Subscribe
David Kappos, former USPTO director, speaking at the CIPA Annual Congress 2025
17 October 2025NewsAmericasSarah Speight

‘All it takes is a post on Truth Social’: Is this patent reform's moment?

A US Senate subcommittee hearing on patent eligibility reform has David Kappos, former USPTO director, believing that “there’s a better chance than ever” of a pending bill becoming law, finds Sarah Speight.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
How impactful is the new USPTO director’s S101 decision?
2 October 2025   As John Squires makes the bold move to allow patentability of an AI-related invention in Ex parte Desjardins, experts broadly welcome the decision—but encourage some caution, finds Sarah Speight.
Americas
All eyes on Squires: What IP experts want from the new USPTO director
23 September 2025   As John Squires is confirmed as the US Patent and Trademark Office's new director, Sarah Speight gathers reaction, and asks: what would you ask the US’ chief IP executive?
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025   Proposed patent legislation will save US innovation and counter the ‘existential threat’ that China poses to the West, hears Sarah Speight.


Editor's picks

Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025

Editor's picks

Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025
Americas
IP agencies vital to pharma and biotech grind to a halt
2 October 2025
Americas
Global vaccine patents rise, as data reveals shift in Big Pharma strategy
1 October 2025
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Killing the golden goose of US drug innovation (Part I): Follow the money
10 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

More features

Novartis fails to block repackaged imports of blockbuster treatment
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
Top pharma, biotech, and medtech experts to gather at LSPN Fall
Protect early, partner wisely: In-house tips for medtech startups
Latham scoops Simmons partner for its London office
Data in the age of AI and why its value lies in quality, not quantity
Simmons loses another senior with litigator’s German move
Morgan Lewis adds regulatory partner to London office